{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:20:28Z","timestamp":1777706428448,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cmi.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:38:48Z","timestamp":1717051128000},"page":"1351-1363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"30","author":[{"given":"Maryam","family":"Ghadimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed A.C.","family":"Siemieniuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afeez Abiola","family":"Hazzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danial","family":"Aminaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnav","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Basmaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Alvarado-Gamarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Likhvantsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Pedro","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Motaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Couban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behnam","family":"Sadeghirad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.05.017_bib1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib2","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"Torres","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2024.05.017_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF01712153","article-title":"Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group","volume":"22","author":"Alvarez-Lerma","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000667","article-title":"Inappropriate empiric therapy impacts complications and hospital resource utilization differentially among different types of bacterial nosocomial pneumonia: a cohort study, United States, 2014\u20132019","volume":"4","author":"Zilberberg","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.cmi.2024.05.017_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2018.04.011","article-title":"Carbapenems vs. alternative beta-lactams for the treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"52","author":"O\u2019Donnell","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2024.05.017_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.chest.2020.10.039","article-title":"Carbapenem antibiotics for the empiric treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"159","author":"Howatt","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2024.05.017_bib8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1183\/09031936.00080206","article-title":"Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia","volume":"29","author":"Siempos","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2024.05.017_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20108","article-title":"Carbapenems versus beta-lactam and beta-lactamase inhibitors for treatment of nosocomial pneumonia: a systematic review and meta-analysis","volume":"9","author":"Cang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.cmi.2024.05.017_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.05.017_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J"},{"key":"10.1016\/j.cmi.2024.05.017_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trial."},{"key":"10.1016\/j.cmi.2024.05.017_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cmi.2024.05.017_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cmi.2024.05.017_bib18","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.cmi.2024.05.017_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A\u00a0GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.05.017_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2014study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2023.03.003","article-title":"GRADE guidance 36: updates to GRADE's approach to addressing inconsistency","volume":"158","author":"Guyatt","year":"2023","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib24","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence\u2014indirectness","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence--publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.06.010","article-title":"Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis","volume":"160","author":"Brignardello-Petersen","year":"2023","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","article-title":"GRADE guidelines 33: addressing imprecision in a network meta-analysis","volume":"139","author":"Brignardello-Petersen","year":"2021","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.05.017_bib30","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2024.05.017_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib32","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000238881","article-title":"Comparative efficacy of ceftriaxone versus ceftazidime in the treatment of nosocomial lower respiratory tract infections","volume":"37","author":"Bassetti","year":"1991","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2024.05.017_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/157488408784293660","article-title":"Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients","volume":"3","author":"Chaudhary","year":"2008","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.cmi.2024.05.017_bib34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/AAC.38.6.1309","article-title":"Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients","volume":"38","author":"Cometta","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF03258463","article-title":"A randomised comparative trial of aztreonam plus cefazolin versus ceftazidime for the treatment of nosocomial pneumonia","volume":"7","author":"Fekete","year":"1994","journal-title":"Drug Investigation"},{"key":"10.1016\/j.cmi.2024.05.017_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/AAC.38.3.547","article-title":"Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group","volume":"38","author":"Fink","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib38","first-page":"624","article-title":"Observation of the therapeutic effect of cefepime in the treatment of nosocomial pneumonia","volume":"34","author":"Gao","year":"1999","journal-title":"Chin Pharm J"},{"key":"10.1016\/j.cmi.2024.05.017_bib39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/BF01700407","article-title":"Prospective, randomised, multicentre study of meropenem versus imipenem\/cilastatin as empiric monotherapy in severe nosocomial infections","volume":"16","author":"Garau","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0732-8893(92)90061-W","article-title":"A\u00a0multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections","volume":"15","author":"Garber","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/26.suppl_B.117","article-title":"Pefloxacin versus imipenem in the therapy of nosocomial lung infections of intensive care unit patients","volume":"26","author":"Giamarellou","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib42","first-page":"40","article-title":"Multi-center, randomised comparative study of ceftazidime vs. cefotaxime in the treatment of patients 65 years of age and older with nosocomial bacterial pulmonary and urinary tract infections","volume":"4","author":"Heinrich","year":"1991","journal-title":"Int J Exp Clin Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s15010-007-6193-x","article-title":"HAP Study Group. A randomized study of sequential intravenous\/oral moxifloxacin in comparison to sequential intravenous ceftriaxone\/oral cefuroxime axetil in patients with hospital-acquired pneumonia","volume":"35","author":"Hoffken","year":"2007","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2024.05.017_bib44","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1128\/AAC.42.11.2966","article-title":"Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis","volume":"42","author":"Jaccard","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib45","first-page":"674","article-title":"Meropenem versus imipenem\/cilastatin in the treatment of hospital acquired infection of lower respiratory tract","volume":"30","author":"Jin","year":"2005","journal-title":"Chin J Antibiot"},{"key":"10.1016\/j.cmi.2024.05.017_bib46","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.rmed.2006.01.004","article-title":"Comparison of piperacillin\/tazobactam and imipenem\/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia","volume":"100","author":"Joshi","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/43.3.389","article-title":"Piperacillin\/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin\/tazobactam Nosocomial Pneumonia Study Group","volume":"43","author":"Joshi","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib48","first-page":"211","article-title":"Controlled clinical study of ceftazidime (3 x 1 g daily) versus piperacillin + tobramycin in patients with nosocomial pneumonia","volume":"3","author":"Koehler","year":"1990","journal-title":"Int J Exp Clin Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0732-8893(92)90086-9","article-title":"Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia","volume":"15","author":"Mangi","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0002-9343(88)90174-X","article-title":"Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia","volume":"85","author":"Mangi","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/36.suppl_A.145","article-title":"Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group","volume":"36","author":"Mouton","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib52","first-page":"1928","article-title":"Controlled randomized prospective study of a ceftazidime-pefloxacin combination versus a ceftazidime-amikacin combination in the empirical treatment of nosocomial pneumonias and septicemias of resuscitation. Preliminary results","volume":"17","author":"Mouton","year":"1988","journal-title":"Presse Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib53","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jac\/31.6.927","article-title":"Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem\/cilastatin. European Study Group","volume":"31","author":"Norrby","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10434-001-0179-1","article-title":"Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study","volume":"8","author":"Raad","year":"2001","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cmi.2024.05.017_bib55","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.05.017_bib56","first-page":"135","article-title":"Ceftazidima vs crystalline sodium penicillin and amikacin in the treatment of nosocomial pneumonia","volume":"15","author":"Ramirez","year":"1999","journal-title":"Medicina Interna de Mexico"},{"key":"10.1016\/j.cmi.2024.05.017_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/j.1875-9114.1984.tb03360.x","article-title":"Ceftazidime versus tobramycin\/ticarcillin in treating hospital acquired pneumonia and bacteremia","volume":"4","author":"Rapp","year":"1984","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2024.05.017_bib58","first-page":"49","article-title":"Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection","volume":"10","author":"Rapp","year":"1991","journal-title":"Clin Pharm"},{"key":"10.1016\/j.cmi.2024.05.017_bib59","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1185\/03007990802179255","article-title":"Efficacy and safety of doripenem versus piperacillin\/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study","volume":"24","author":"Rea-Neto","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cmi.2024.05.017_bib60","first-page":"272","article-title":"Nosocomial pneumonia: third-group chinolone versus clindamycin\/ceftriaxone in modulation of the acute phase reaction and outcome and cost efficacy","volume":"91","author":"Reith","year":"2006","journal-title":"Int Surg"},{"key":"10.1016\/j.cmi.2024.05.017_bib61","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/clinids\/20.5.1217","article-title":"Ceftazidime monotherapy vs. ceftriaxone\/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group","volume":"20","author":"Rubinstein","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib62","first-page":"89","article-title":"Prospective, randomized comparison of intravenous and oral ciprofloxacin with intravenous ceftazidime in the treatment of nosocomial pneumonia","volume":"8","author":"Saginur","year":"1997","journal-title":"Can J Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s15010-006-5020-0","article-title":"Piperacillin\/tazobactam vs imipenem\/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study","volume":"34","author":"Schmitt","year":"2006","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2024.05.017_bib64","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/00003246-199710000-00015","article-title":"Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group","volume":"25","author":"Sieger","year":"1997","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2024.05.017_bib65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0732-8893(95)00083-M","article-title":"Cefotaxime versus ceftriaxone for the treatment of nosocomial pneumonia. Results of a multicenter study","volume":"22","author":"Shah","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000238716","article-title":"Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime","volume":"35","author":"Torres","year":"1989","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2024.05.017_bib67","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/thorax.55.12.1033","article-title":"Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem\/cilastatin","volume":"55","author":"Torres","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.cmi.2024.05.017_bib68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0149-2918(03)80091-7","article-title":"Levofloxacin compared with imipenem\/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study","volume":"25","author":"West","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.cmi.2024.05.017_bib69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10096-006-0193-0","article-title":"Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit","volume":"25","author":"Yakovlev","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib70","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.cmi.2022.03.014","article-title":"Exposure to\u00a0World Health Organization's AWaRe antibiotics and isolation of multidrug\u00a0resistant bacteria: a systematic review and meta-analysis","volume":"28","author":"Sulis","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2024.05.017_bib71","series-title":"FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects","year":"2018"},{"key":"10.1016\/j.cmi.2024.05.017_bib72","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/ofid\/ofy343","article-title":"Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY antimicrobial surveillance program, 1997\u20132016","volume":"6","author":"Shortridge","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2024.05.017_bib73","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/jac\/dkz074","article-title":"Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997\u20132016)","volume":"74","author":"Sader","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24002544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24002544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T19:22:23Z","timestamp":1728933743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24002544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1198743X24002544"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.05.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empiric antibiotic regimens in adults with non-ventilator-associated hospital-acquired pneumonia: a systematic review and network meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}